PriceTargets.com logo

NRx Pharmaceuticals - NRXP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $36.75
  • Forecasted Upside: 1,609.30%
  • Number of Analysts: 6
  • Breakdown:
  • 2 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.15 As of 02/2/2026 05:00 PM ET
▲ +0.05 (2.38%)

This chart shows the closing price for NRXP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NRx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NRXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NRXP

Analyst Price Target is $36.75
▲ +1,609.30% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for NRx Pharmaceuticals in the last 3 months. The average price target is $36.75, with a high forecast of $48.00 and a low forecast of $25.00. The average price target represents a 1,609.30% upside from the last price of $2.15.

This chart shows the closing price for NRXP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in NRx Pharmaceuticals. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/26/2026Zacks ResearchDowngradeHold ➝ Strong Sell
1/21/2026HC WainwrightReiterated RatingBuy ➝ Buy
1/15/2026BTIG ResearchReiterated RatingBuy ➝ Buy$25.00
1/5/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00
1/2/2026Ascendiant Capital MarketsReiterated RatingBuy ➝ Buy$47.00 ➝ $48.00
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/23/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00
12/3/2025BTIG ResearchReiterated RatingBuy ➝ Buy$25.00
12/2/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00
11/17/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00
11/10/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00
10/30/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$46.00 ➝ $47.00
10/21/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00
10/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/1/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/25/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00
9/10/2025Zacks ResearchUpgradeHold
9/8/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00
9/8/2025HC WainwrightInitiated CoverageBuy ➝ Buy$40.00
8/25/2025BTIG ResearchReiterated RatingBuy ➝ Buy
8/19/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
8/11/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
8/4/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
6/20/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
6/6/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
5/16/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
4/30/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
4/29/2025Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$45.00 ➝ $46.00
4/2/2025BTIG ResearchInitiated CoverageBuy$18.00
3/31/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
3/24/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
3/20/2025HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
3/17/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
3/14/2025HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
1/28/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
1/6/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
12/31/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
12/2/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$44.00 ➝ $45.00
11/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
10/21/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
9/12/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$43.00 ➝ $44.00
8/5/2024HC WainwrightBoost TargetBuy ➝ Buy$2.00 ➝ $19.00
6/7/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$50.00 ➝ $43.00
3/17/2023Dawson JamesReiterated RatingBuy
2/2/2023HC WainwrightReiterated RatingBuy$200.00
11/9/2022Ascendiant Capital MarketsInitiated CoverageBuy$400.00
6/30/2022HC WainwrightInitiated CoverageBuy$200.00
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 32 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
Mentions as of
9/5/2025
  • 11 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 4 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
Mentions as of
12/4/2025
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NRx Pharmaceuticals logo
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $2.15
Low: $2.09
High: $2.17

50 Day Range

MA: $2.31
Low: $1.98
High: $2.71

52 Week Range

Now: $2.15
Low: $1.58
High: $3.84

Volume

270,171 shs

Average Volume

1,731,007 shs

Market Capitalization

$63.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of NRx Pharmaceuticals?

The following Wall Street analysts have issued research reports on NRx Pharmaceuticals in the last year: Ascendiant Capital Markets, BTIG Research, D. Boral Capital, HC Wainwright, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for NRXP.

What is the current price target for NRx Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for NRx Pharmaceuticals in the last year. Their average twelve-month price target is $36.75, suggesting a possible upside of 1,650.0%. Ascendiant Capital Markets has the highest price target set, predicting NRXP will reach $48.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $25.00 for NRx Pharmaceuticals in the next year.
View the latest price targets for NRXP.

What is the current consensus analyst rating for NRx Pharmaceuticals?

NRx Pharmaceuticals currently has 2 sell ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NRXP, but not buy more shares or sell existing shares.
View the latest ratings for NRXP.

What other companies compete with NRx Pharmaceuticals?

Other companies that are similar to NRx Pharmaceuticals include Enlivex Therapeutics, Aurora Cannabis, Coherus Oncology, Maxpro Capital Acquisition and Jyong Biotech. Learn More about companies similar to NRx Pharmaceuticals.

How do I contact NRx Pharmaceuticals' investor relations team?

NRx Pharmaceuticals' physical mailing address is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. The company's listed phone number is (484) 254-6134 and its investor relations email address is [email protected]. The official website for NRx Pharmaceuticals is www.bigrockpartners.com. Learn More about contacing NRx Pharmaceuticals investor relations.